Trial Profile
A Phase I/II Study of Erlotinib and Romidepsin in Advanced Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Jan 2021 Phase changed from I/II to I. Study design sequential added.
- 03 Mar 2011 New trial record